Case Reports
doi: 10.1016/j.jtho.2018.06.022.
Recurrent Pneumonitis Induced by Atezolizumab (Anti-Programmed Death Ligand 1) in NSCLC Patients Who Previously Experienced Anti-Programmed Death 1 Immunotherapy-Related Pneumonitis
Affiliations
- PMID: 30368415
- DOI: 10.1016/j.jtho.2018.06.022
Item in Clipboard
Case Reports
Recurrent Pneumonitis Induced by Atezolizumab (Anti-Programmed Death Ligand 1) in NSCLC Patients Who Previously Experienced Anti-Programmed Death 1 Immunotherapy-Related Pneumonitis
J Thorac Oncol.
2018 Nov.
Free article
No abstract available
Similar articles
-
Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Trials.Chest. 2017 Aug;152(2):271-281. doi: 10.1016/j.chest.2017.04.177. Epub 2017 May 10. Chest. 2017. PMID: 28499515 Review.
-
Severe nivolumab-induced pneumonitis preceding durable clinical remission in a patient with refractory, metastatic lung squamous cell cancer: a case report.J Hematol Oncol. 2017 Feb 28;10(1):64. doi: 10.1186/s13045-017-0433-z. J Hematol Oncol. 2017. PMID: 28245875 Free PMC article.
-
Development of Halo Nevi in a Lung Cancer Patient: A Novel Immune-Related Cutaneous Event from Atezolizumab.J Drugs Dermatol. 2017 Oct 1;16(10):1047-1049. J Drugs Dermatol. 2017. PMID: 29036261
-
Fatal outcome of atezolizumab in a patient with immune-mediated pneumonitis, thrombocytopenia, and cardiac dysfunction: A case report .Int J Clin Pharmacol Ther. 2019 Dec;57(12):607-611. doi: 10.5414/CP203448. Int J Clin Pharmacol Ther. 2019. PMID: 31488241
-
Advances in the Treatment of Non-small Cell Lung Cancer: Focus on Nivolumab, Pembrolizumab, and Atezolizumab.BioDrugs. 2016 Oct;30(5):397-405. doi: 10.1007/s40259-016-0187-0. BioDrugs. 2016. PMID: 27411930 Review.
Cited by
-
TFAP2A promotes cervical cancer via a positive feedback pathway with PD‑L1.Oncol Rep. 2023 Jun;49(6):114. doi: 10.3892/or.2023.8551. Epub 2023 Apr 21. Oncol Rep. 2023. PMID: 37083077 Free PMC article.
-
Safety of Tepotinib Challenge after Capmatinib-Induced Pneumonitis in a Patient with Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation: A Case Report.Int J Mol Sci. 2022 Oct 5;23(19):11809. doi: 10.3390/ijms231911809. Int J Mol Sci. 2022. PMID: 36233109 Free PMC article.
-
Case report: Pneumonia with clinical symptoms precedes imaging evidence after immune checkpoint inhibitors combined with radiotherapy in lung squamous cell cancer.Front Immunol. 2022 Sep 15;13:998516. doi: 10.3389/fimmu.2022.998516. eCollection 2022. Front Immunol. 2022. PMID: 36189237 Free PMC article.
-
First line Immunotherapy for Non-Small Cell Lung Cancer.Pharmaceuticals (Basel). 2020 Nov 8;13(11):373. doi: 10.3390/ph13110373. Pharmaceuticals (Basel). 2020. PMID: 33171686 Free PMC article. Review.
-
High-Risk HPV Oncoproteins and PD-1/PD-L1 Interplay in Human Cervical Cancer: Recent Evidence and Future Directions.Front Oncol. 2020 Jun 30;10:914. doi: 10.3389/fonc.2020.00914. eCollection 2020. Front Oncol. 2020. PMID: 32695664 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
